Clinical trials: Dementia, Senile
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Alzheimer's Disease
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
The purpose of the study is to examine the safety, tolerability, immunogenicity and pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive impairment.
- Trial name
- NCT01548430
- Testing
- TTP4000
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- vTv Therapeutics
Alzheimer's Disease
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
The primary objective of this study is to evaluate the safety and tolerability of multiple doses of Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb) in participants with prodromal or mild Alzheimer's Disease (AD).
- Trial name
- PRIME (NCT01677572)
- Testing
- Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)
- Where
- 32 sites in United States
- Volunteers
- 197 people
- Sponsor
- Biogen
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
The study aims to evaluate the effect of acoramidis on cardiac functional and structural improvement in participants with ATTR-CM.
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis
- Trial name
- ASCEND-ATTR (NCT07695701)
- Testing
- Acoramidis (AG10) oral tablet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Alzheimer's Disease
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
This study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid plaque density as measured by histopathological assessment.
- Trial name
- NCT01447719
- Testing
- florbetapir F 18
- Where
- 22 sites in United States
- Volunteers
- 110 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer's Disease
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
- Trial name
- NCT05744401
- Testing
- AL002
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 197 people
- Sponsor
- Alector Inc.
Dementia, Dementia Alzheimers
A Spanish-language Caregiver-Enabled Care Program
The purpose of the study is to develop and test the feasibility of a nonmedical digital health intervention, the Spanish-language Caregiver-Enabled Care Program (CECP), with Spanish-speaking caregivers of persons with dementia…
- Conditions
- Dementia, Dementia Alzheimers, Alzheimer Disease, Caregiver
- Trial name
- CECP (NCT06631144)
- Testing
- Spanish-language Caregiver-Enabled Care Program (CECP)
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Ceresti Health, Inc.
Alzheimer's Disease
Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants
The primary objectives of this study are to evaluate the absolute bioavailability of a single, fixed sub-cutaneous (SC) dose of aducanumab compared with a single, weight-based intra-venous (IV) dose in healthy participants and to…
- Trial name
- NCT02782975
- Testing
- aducanumab
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Alzheimer's Disease
A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
The purpose of this study is to demonstrate that the change of attention measure is correlated with the changes of caregiver's burden after treatment with galantamine.
- Trial name
- NCT01734395
- Testing
- Galantamine
- Volunteers
- 1,882 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cognition Disorders
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer…
- Trial name
- A4 (NCT02008357)
- Testing
- Solanezumab
- Where
- 68 sites in United States, Australia and 2 more
- Volunteers
- 1,169 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
- Trial name
- TARBELA-AD (NCT07781657)
- Testing
- RO7568282
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.
Study of the Safety, tolerability and pharmacokinetics with multiple doses of donepezil patch in healthy male subjects
- Trial name
- NCT02178124
- Testing
- Donepezil
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Icure Pharmaceutical Inc.
Alzheimer's Disease
[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)
The purpose of this open-label, 3-part study is to investigate the safety and efficacy of [11C]MK-6884 as a positron emission tomography (PET) imaging agent for quantifying muscarinic 4 (M4) positive allosteric modulator (PAM)…
- Trial name
- NCT02621606
- Testing
- [11C]MK-6884
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dementia Alzheimer's Type
Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Primary Objective: To demonstrate the efficacy of at least one dose of SAR110894 (H3 receptor antagonist) in comparison to placebo on cognitive performance in patients with mild to moderate Alzheimer's disease (AD) while on…
- Trial name
- NCT01266525
- Testing
- SAR110894, Donepezil
- Where
- 82 sites in United States, Australia and 7 more
- Volunteers
- 291 people
- Sponsor
- Sanofi
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's and Blood Glucose Levels
The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's…
- Trial name
- NCT04614376
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bio Conscious Technologies Inc.
Alzheimer Disease
A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease
The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as…
- Trial name
- NCT07612150
- Testing
- TML-6
- Volunteers
- 210 people
- Sponsor
- Merry Life Biomedical Co., Ltd.
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg…
- Trial name
- NCT04715750
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Life Molecular Imaging GmbH
Alzheimer's Disease, Central Nervous System Diseases
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
This study is being conducted to determine the safety, tolerability, and pharmacokinetics (PK) of three different doses of an investigational medication, EVP-6124, in individuals with mild to moderate Alzheimer's disease who are…
- Trial name
- NCT00766363
- Testing
- EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- FORUM Pharmaceuticals Inc
Healthy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01887535
- Testing
- JNJ-54861911 3 mg, JNJ-54861911 10 mg, JNJ-54861911 30 mg
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.